Extrarenal vitamin D activation and interactions between vitamin D2, vitamin D3, and vitamin D analogs

Annual Review of Nutrition

Volumn 33, Issue , 2013, Pages 23-44

  Jones, Glenville ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

1 ,25 dihydroxyvitamin D; CYP24A1; CYP27B1; CYP2R1; CYP3A4; Hydroxyvitamin D; Vitamin D2 vitamin D3

Indexed keywords

CALCIUM; CHOLESTANETRIOL 26 MONOOXYGENASE; COLECALCIFEROL; CYTOCHROME P450 3A4; ERGOCALCIFEROL; VITAMIN D DERIVATIVE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CALCIUM HOMEOSTASIS; CELL DIFFERENTIATION; CELL DIVISION; DRUG ACTIVATION; GENE EXPRESSION; HUMAN; HYDROXYLATION; HYPERCALCEMIA; HYPERCALCIURIA; KIDNEY CALCIFICATION; NONHUMAN; NUTRITION; PRIORITY JOURNAL; RICKETS; SIGNAL TRANSDUCTION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN METABOLISM;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ANIMALS; CHOLECALCIFEROL; DIET; DIETARY SUPPLEMENTS; ERGOCALCIFEROLS; HUMANS; SIGNAL TRANSDUCTION; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84880677429     PISSN: 01999885     EISSN: 15454312     Source Type: Book Series    
DOI: 10.1146/annurev-nutr-071812-161203     Document Type: Article

References (113)

1. Adams JS, Singer FR, Gacad MA, Sharma OP, Hayes MJ, et al. 1985. Isolation and structural identification of 1,25-dihydroxyvitamin D3 produced by cultured alveolar macrophages in sarcoidosis. J. Clin. Endocrinol. Metab. 60:960-69
2. Ahn J, Yu K, Stolzenberg-Solomon R, Simon KC, McCullough ML, et al. 2010. Genome-wide association study of circulating vitamin D levels. Hum. Mol. Genet. 19:2739-45
3. Akutsu N, Lin R, Bastien Y, Bestawros A, Enepekides DJ, et al. 2001. Regulation of gene expression by 1α,25-dihydroxyvitamin D3 and its analog EB1089 under growth-inhibitory conditions in squamous carcinoma cells. Mol. Endocrinol. 15:1127-39
4. Al-Aly Z, Qazi RA, Gonzalez EA, Zeringue A, Martin KJ. 2007. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol with CKD. Am. J. Kidney Dis. 50:59-68
5. Alvarez JA, Law J, Coakley KE, Zughaier SM, Hao L, et al. 2012. High dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind placebo-controlled trial. Am. J. Clin. Nutr. 96:672-79
6. Armas LA, Hollis BW, Heaney RP. 2004. VitaminD2 is much less effective than vitaminD3 in humans. J. Clin. Endocrinol. Metab. 89:5387-91
7. Barbour GL, Coburn JW, Slatopolsky E, Norman AW, Horst RL. 1981. Hypercalcemia in an anephric patient with sarcoidosis: evidence for extrarenal generation of 1,25-dihydroxyvitamin D. N. Engl. J. Med. 305:440-43
8. Bhattacharyya MH, DeLuca HF. 1973. The regulation of rat liver calciferol-25-hydroxylase. J. Biol. Chem. 248:2969-73
9. Biancuzzo RM, Clarke N, Reitz RE, Travison TG, Holick MF. 2013. Serum concentrations of 1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 in response to vitamin D2 and vitamin D3 supplementation. J. Clin. Endocrinol. Metab. 98:973-79
10. Binkley N. 2012. Vitamin D and osteoporosis-related fracture. Arch. Biochem. Biophys. 523:115-22
11. Binkley N, Gemar D, Engelke J, Gangnon R, Ramamurthy R, et al. 2011. Evaluation of ergocalciferol or cholecalciferol dosing 1600 IU/daily or 50,000 IU monthly in older adults. J. Clin. Endocrinol. Metab. 96:981-88
12. Bischoff-Ferrari HA, Dietrich T, Orav EJ, Hu FB, Zhang Y, et al. 2004. Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged or = 60 y. Am. J. Clin. Nutr. 80:752-58
13. Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, et al. 2008. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr. Rev. 29:726-76
14. Briese S, Wiesner S, Will JC, Lembcke A, Opgen-Rhein B, et al. 2006. Arterial and cardiac disease in young adults with childhood-onset end-stage renal disease-impact of calcium and vitamin D therapy. Nephrol. Dial. Transplant. 21:1906-14
15. Brown AJ, Finch J, Takahashi F, Slatopolsky E. 2000. Calcemic activity of 19-nor-1,25(OH)2D2 decreases with duration of treatment. J. Am. Soc. Nephrol. 11:2088-94
16. Carter GD. 2012. 25-hydroxyvitamin D: a difficult analyte. Clin. Chem. 58:486-88
17. Cashman KD, Hill TR, Lucey AJ, Taylor N, Seamans KM, et al. 2008. Estimation of the dietary requirement for vitamin D in healthy adults. Am. J. Clin. Nutr. 88:1535-42
18. Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW. 2004. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc. Natl. Acad. Sci. USA 101:7711-15
19. Clemens TL, Zhou XY, Myles M, Endres D, Lindsay R. 1986. Serum vitamin D2 and vitamin D3 metabolite concentrations and absorption of vitamin D2 in elderly subjects. J. Clin. Endocrinol. Metab. 63:656-60
20. Dardenne O, Prud?homme J, Arabian A, Glorieux FH, St-Arnaud R. 2001. Targeted inactivation of the 25-hydroxyvitaminD3-1α-hydroxylase gene (CYP27B1) creates an animalmodel of pseudovitamin D-deficiency rickets. Endocrinology 142:3135-41
21. DeLuca HF. 1974. Vitamin D: the vitamin and the hormone. Fed. Proc. 33:2211-19
22. Delvin EE, Glorieux FH, Dussault M, Bourbonnais R, Walters G. 1978. Simultaneous measurement of serum 25-hydroxycholecalciferol and 25-hydroxyergocalciferol. Med. Biol. 57:165-70
23. Dowd DR, MacDonald PN. 2011. Co-regulators of VDR-mediated gene expression. See Ref. 24a, pp. 193-210
24. Dusso AS, Finch J, Brown A, Ritter C, Delmez J, et al. 1991. Extrarenal production of calcitriol in normal and uremic humans. J. Clin. Endocrinol. Metab. 72:157-64
25. Feldman D, Pike JW, Adams JS, eds. 2011. Vitamin D. San Diego, CA: Academic. 3rd ed.
26. Fournier A, Harbouche L, Mansour J, Shahapuni I. 2007. Impact of calcium and vitamin D therapy on arterial and cardiac disease in young adults with childhood-onset end-stage renal disease. Nephrol. Dial. Transplant. 22:956-57
27. Fraser D, Kooh SW, Kind HP, Holick MF, Tanaka Y, DeLuca HF. 1973. Pathogenesis of hereditary vitamin D-dependent rickets. An inborn error of vitamin D metabolism involving defective conversion of 25-hydroxyvitamin D to 1α,25-dihydroxyvitamin D. N. Engl. J. Med. 289:817-22
28. Fraser DR, Kodicek E. 1970. Unique biosynthesis by kidney of a biologically active vitamin D metabolite. Nature 228:764-66
29. Gallagher JC, Bishop CW, Knutson JC, Mazess RB, DeLuca HF. 1994. Effects of increasing doses of 1α-hydroxyvitaminD2 on calcium homeostasis in postmenopausal women. J. Bone Miner. Res. 9:607-14
30. Gallagher JC, Sai A, Templin T 2nd, Smith L. 2012. Dose response to vitamin D supplementation in postmenopausal women: a randomized trial. Ann. Intern. Med. 156:425-37
31. Glendenning P, Chew GT, Seymour HM, Gillett MJ, Goldswain PR, et al. 2009. Serum 25-hydroxyvitamin D levels in vitamin D-insufficient hip fracture patients after supplementation with ergocalciferol or cholecalciferol. Bone 45:870-75
32. Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ. 2004. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am. J. Nephrol. 24:503-10
33. GrantWB, Garland CF. 2002. Evidence supporting the role of vitaminDin reducing the risk of cancer. J. Intern. Med. 252:178-79
34. Griffin LM, Denburg MR, Shults J, Furth SL, Salusky IB, et al. 2013. Nutritional vitamin D use in chronic kidney disease: a survey of pediatric nephrologists. Pediatr. Nephrol. 28:265-75
35. Guo Y-D, Strugnell S, Back DW, Jones G. 1993. Substrate specificity of the liver mitochondrial cytochrome P-450, CYP-27, towards vitamin D and its analogs. Proc. Natl. Acad. Sci. USA 90:8668-72
36. Gupta RP, He YA, Patrick KS, Halpert J.R., Bell NH. 2005. CYP3A4 is a vitamin D-24-and 25-hydroxylase: analysis of structure function by site-directed mutagenesis. J. Clin. Endocrinol. Metab. 90:1210-19
37. Gupta RP, Hollis BW, Patel SB, Patrick KS, Bell NH. 2004. CYP3A4 is a human microsomal vitamin D 25-hydroxylase. J. Bone Miner. Res. 19:680-88
38. Hartwell D, Tjellesen L, Christiansen C, Rodbro P. 1989. Metabolism of vitamin D2 and vitamin D3 in patients on anticonvulsant therapy. Acta Neurol. Scand. 79:487-92
39. Haussler MR, Whitfield GK, Haussler C, Hsieh J-C, Jurutka PW. 2011. Nuclear vitamin D receptor: natural ligands, molecular structure-function and transcriptional control of vital genes. See Ref. 24a, pp. 137-170
40. Heaney RP, Armas LA, Shary J.R., Bell NH, Binkley N, Hollis BW. 2008. 25-Hydroxylation of vitamin D3: relation to circulating vitamin D3 under various conditions. Am. J. Clin. Nutr. 87:1738-42
41. Hewison M, Adams JS. 2011. Extrarenal 1α-hydroxylase. See Ref. 24a, pp. 777-806
42. Holick MF. 2004. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers and cardiovascular disease. Am. J. Clin. Nutr. 80(Suppl.):1678-88S
43. Holick MF. 2007. Vitamin D deficiency. N. Engl. J. Med. 357:266-81
44. Holick MF. 2011. Photobiology of vitamin D. See Ref. 24a, pp. 13-22
45. Holick MF, Biancuzzo RM, Chen TC, Klein EK, Young A, et al. 2008. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J. Clin. Endocrinol. Metab. 93:677-81
46. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, et al. 2012. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J. Clin. Endocrinol. Metab. 97:1153-58
47. Holick MF, Schnoes HK, DeLuca HF, Gray RW, Boyle IT, Suda T. 1972. Isolation and identification of 24,25-dihydroxycholecalciferol, a metabolite of vitamin D made in the kidney. Biochemistry 11: 4251-55
48. Houghton LA, Vieth R. 2006. The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am. J. Clin. Nutr. 84:694-97
49. Hunt RD, Garcia FG, Walsh RJ. 1972. A comparison of the toxicity of ergocalciferol and cholecalciferol in rhesus monkeys (Macaca mulatta). J. Nutr. 102:975-86
50. Inst. Med. 2011. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: Natl. Acad. Press
51. Jones G. 2007. Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extrarenal 1α-hydroxylase in the classical and non-classical actions of 1α,25-dihydroxyvitamin D3. Semin. Dial. 20:316-24
52. Jones G. 2010. Editorial: why dialysis patients need combination therapy with cholecalciferol and a calcitriol analog. Semin. Dial. 23:239-43
53. Jones G. 2012. Vitamin D Analogs. Rheum. Disease Clin. N. Am. 38:207-32
54. Jones G. 2012. Vitamin D. In Modern Nutrition in Health and Disease, ed. AC Ross, B Caballero, RJ Cousins, KL Tucker, TR Ziegler, pp. 278-92. Philadelphia, PA: Lippincott, Williams & Wilkins. 11th ed.
55. Jones G, Byford V, Helvig C, Petkovich M. 2009. Differential disposition of vitamin D2 does not involve CYP24A1. Presented at 14th Intl. Vitamin D Workshop, Brugge, Belgium
56. Jones G, Byford V, West S, Masuda S, Ibrahim G, et al. 2006. Hepatic activation and inactivation of clinically relevant vitamin D analogs and prodrugs. Anticancer. Res. 26:2589-96
57. Jones G, Horst RL, Carter G, Makin HLJ. 2007. Contemporary diagnosis and treatment of vitamin D-related disorders. J. Bone Miner. Res. 22(Suppl. 2):V11-15
58. Jones G, Kaufmann M, Prosser DE. 2012. 25-hydroxyvitamin D3-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D. Arch. Biochem. Biophys. 523:9-18
59. Jones G, Strugnell S, DeLuca HF. 1998. Current understanding of the molecular actions of vitamin D. Physiol. Rev. 78:1193-231
60. Judd SE, Tangpricha V. 2011. VitaminDtherapy and cardiovascular health.Am. J. Med. Sci. 338:40-44
61. Kidney Dis. Improv. Glob. Outcomes (KDIGO) CKD-MBD Work Group. 2009. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney diseasemineral and bone disorder (CKD-MBD). Kidney Int. Suppl. 113:1-130
62. Kidney Dis. Outcomes Qual. Initiat. 2003. Clinical practice guidelines for bonemetabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 42(Suppl. 3):S1-202
63. Kramer H, Sempos C, CaoG, Luke A, ShohamD, et al. 2012. Mortality rates across 25-hydroxyvitamin D [25(OH)D] levels among adults with and without estimated glomerular filtration rate <60 ml/min/1.73 m2: the third National Health and Nutrition Examination Survey. PLoS ONE 7 (10): e47458
64. Leventis P, Kiely PD. 2009. The tolerability and biochemical effects of high-dose vitamin D2 and vitamin D3 supplementation in patients with vitamin D deficiency. Scand. J. Rheumatol. 38:149-53
65. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, et al. 2006. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311:1770-73
66. Looker AC, Johnson CL, Lacher DA, PfeifferCM, Schleicher RL, Sempos CT. 2011. VitaminDstatus: United States, 2001-2006. NCHS Data Brief 59:1-8
67. MakinG, LohnesD, Byford V, Ray R, Jones G. 1989. Target cell metabolism of 1,25-dihydroxyvitamin D3 to calcitroic acid. Evidence for a pathway in kidney and bone involving 24-oxidation. Biochem. J. 262:173-80
68. Martinez I, Saracho R, Montenegro J, Llach F. 1996. A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism. Nephrol. Dial. Transplant. 11(Suppl. 3):22-28
69. Masuda S, Byford V, Arabian A, Sakai Y, Demay MB, et al. 2005. Altered pharmacokinetics of 1α,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse. Endocrinology 146:825-34
70. Meir T, Levi R, Lieben L, Libutti S, Carmeliet G, et al. 2009. Deletion of the vitamin D receptor specifically in the parathyroid demonstrates a limited role for the receptor in parathyroid physiology. Am. J. Physiol. Renal Physiol. 297:F1192-98
71. Ohyama Y, Ozono K, UchidaM, Shinki T, Kato S, et al. 1994. Identification of a vitamin D-responsive element in the 5′-flanking region of the rat 25-hydroxyvitamin D3 24-hydroxylase gene. J. Biol. Chem. 269:10545-50
72. Panda DK, Miao D, Tremblay ML, Sirois J, Farookhi R, et al. 2001. Targeted ablation of the 25-hydroxyvitamin D 1α-hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc. Nat. Acad. Sci. USA 98:7498-503
73. Park EA. 1940. The therapy of rickets. JAMA 115:370-79
74. Petchey WG, Hickman IJ, Prins JB, Hawley CM, Johnson DW, Isbel NM. 2013. Vitamin D does not improve the metabolic health of patients with chronic kidney disease stage 3-4: a randomized controlled trial. Nephrology (Carlton) 18:26-35
75. Petkovich M, Helvig C, Epps T. 2011. CYP24A1 regulation in health and disease. See Ref. 24a, pp. 1525-54
76. Pike JW. 1991. VitaminD3 receptors: structure and function in transcription. Annu. Rev. Nutr. 11:189-216
77. Pike JW, Zella LA, Meyer MB, Fretz JA, Kim S. 2007. Molecular actions of 1,25-dihydroxyvitamin D3 on genes involved in calcium homeostasis. J. Bone Miner. Res. 22(Suppl. 2):V16-19
78. Posner GH, Helvig C, Cuerrier D, Collop D, Kharebov A, et al. 2010. Vitamin D analogues targeting CYP24 in chronic kidney disease. J. Steroid Biochem. Mol. Biol. 121(1-2):13-19
79. Prosser DE, Kaufmann M, O?Leary B, Byford V, Jones G. 2007. Single A326G mutation converts hCYP24A1 from a 25-OH-D3-24-hydroxylase into-23-hydroxylase generating 1α,25-(OH)2D3-26,23-lactone. Proc. Natl. Acad. Sci. USA 104:12673-78
80. Rapuri PB, Gallagher JC, Haynatzki G. 2004. Effect of vitamin D2 and vitamin D3 supplement use on serum 25OHD concentration in elderly women in summer and winter. Calcif. Tissue Int. 74:150-56
81. Reddy GS, TserngKY. 1989. Calcitroic acid, end product of renal metabolism of 1,25-dihydroxyvitamin D3 through C-24 oxidation pathway. Biochemistry 28:1763-69
82. Roborgh J.R., de Man T. 1959. The hypercalcemic activity of dihydrotachysterol2 and dihydrotachysterol3 and of the vitamins D2 and D3: comparative experiments on rats. Biochem. Pharmacol. 2:1-6
83. Roborgh J.R., de Man T. 1960. The hypercalcemic activity of dihydrotachysterol2 and dihydrotachysterol3 and of the vitamins D2 and D3 after intravenous injection of the aqueous preparations. 2. Comparative experiments on rats. Biochem. Pharmacol. 3:277-82
84. Romagnoli E, Mascia ML, Cipriani C, Fassino V, Mazzei F, et al. 2008. Short-and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. J. Clin. Endocrinol. Metab. 93:3015-20
85. Rosen CJ, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. 2012. IOM committee members respond to Endocrine Society vitamin D guideline. J. Clin. Endocrinol. Metab. 97:1146-52
86. Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, et al. 2003. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1α,25-dihydroxyvitamin D3 production. J. Biol. Chem. 278:2206-11
87. Santiso-Mere D, Sone T, Hilliard GM 4th, Pike JW, McDonnell DP. 1993. Positive regulation of the vitamin D receptor by its cognate ligand in heterologous expression systems. Mol. Endocrinol. 7:833-39
88. Schlingmann KP, Kaufmann M, Weber S, Irwin A, Goos C, et al. 2011. Mutations of CYP24A1 and idiopathic infantile hypercalcemia. N. Engl. J. Med. 365:410-21
89. SchmidtDR, Mangelsdorf DJ. 2008. Nuclear receptors of the enteric tract: guarding the frontier. Nutr. Rev. 66(10 Suppl. 2):S88-97
90. Shephard RM, DeLuca HF. 1980. Plasma concentrations of vitamin D3 and its metabolites in the rat as influenced by vitamin D3 or 25-hydroxvitamin D3 intakes. Arch. Biochem. Biophys. 202:43-53
91. Somjen D, Katzburg S, Stern N, Kohen F, Sharon O, et al. 2007. 25-Hydroxyvitamin D3-1α-hydroxylase expression and activity in cultured human osteoblasts and their modulation by parathyroid hormone, estrogenic compounds and dihydrotestosterone. J. Steroid Biochem. Mol. Biol. 107:238-44
92. St-Arnaud R. 1999. Targeted inactivation of vitamin D hydroxylases in mice. Bone 25:127-29
93. St-Arnaud R, Messerlian S, Moir JM, Omdahl JL, Glorieux FH. 1997. The 25-hydroxyvitamin D 1-α-hydroxylase gene maps to the pseudovitamin D-deficiency rickets (PDDR) disease locus. J. Bone Miner. Res. 12:1552-59
94. Strushkevich N, Usanov SA, Plotnikov AN, Jones G, Park H-W. 2008. Structural analysis of CYP2R1 in complex with vitamin D3. J. Mol. Biol. 380:95-106
95. Stubbs J.R., Idiculla A, Slusser J, Menard R, Quarles LD. 2010. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J. Am. Soc. Nephrol. 21:353-61
96. Stumpf WE. 1995. Vitamin D sites and mechanisms of action: a histochemical perspective. Reflections on the utility of autoradiography and cytopharmacology for drug targeting. Histochem. Cell Biol. 104:417-27
97. Takeyama K, Kitanaka S, Sato T, Kobori M, Yanagisawa J, Kato S. 1997. 25-Hydroxyvitamin D3 1α-hydroxylase and vitamin D synthesis. Science 277:1827-30
98. Tebben PJ, Milliner DS, Horst RL, Harris PC, SinghRJ, et al. 2012. Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy. J. Clin. Endocrinol. Metab. 97:E423-27
99. Thacher TD, Fischer PR, Obadofin MO, Levine MA, Singh RJ, Pettifor JM. 2010. Comparison of metabolism of vitamins D2 and D3 in children with nutritional rickets. J. Bone Miner. Res. 25:1988-89
100. Thompson PD, Jurutka PW, WhitfieldGK, Myskowski SM, Eichhorst KR, et al. 2002. Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements. Biochem. Biophys. Res. Commun. 299:730-38
101. Thummel KE, Brimer C, Yasuda K, Thottassery J, Senn T, et al. 2001. Transcriptional control of intestinal cytochrome P-450 3A by 1α,25-dihydroxy vitamin D3. Mol. Pharmacol. 60:1399-406
102. Tjellesen L, Hummer L, Christiansen C, Rodbro P. 1986. Different metabolism of vitamin D2/D3 in epileptic patients treated with phenobarbitone/phenytoin. Bone 7:337-42
103. Trang HM, Cole DE, Rubin LA, Pierratos A, Siu S, Vieth R. 1998. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am. J. Clin. Nutr. 68: 854-58
104. Tripkovic L, Lambert H, Hart K, Smith CP, Bucca G, et al. 2012. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. Am. J. Clin. Nutr. 95:1357-64
105. Urushino N, Yasuda K, Ikushiro S, Kamakura M, Ohta M, Sakaki T. 2009. Metabolism of 1α,25-dihydroxyvitamin D2 by human CYP24A1. Biochem. Biophys. Res. Commun. 384:144-48
106. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, et al. 2010. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 376:180-88
107. Wang Y, Zhu J, DeLucaHF. 2012. Where is the vitaminDreceptor? Arch. Biochem. Biophys. 523:123-33
108. White JH. 2004. Profiling 1,25-dihydroxyvitamin D3-regulated gene expression by microarray analysis. J. Steroid Biochem. Mol. Biol. 89-90:239-44
109. Xu Y, Hashizume T, Shuhart MC, Davis CL, NelsonWL, et al. 2006. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1α,25- dihydroxyvitamin D3: implications for drug-induced osteomalacia. Mol. Pharmacol. 69:56-65
110. Yoshizawa T, Handa Y, Uematsu Y, Takeda S, Sekine K, et al. 1997. Mice lacking the vitamin D receptor exhibit impaired bone metabolism, uterine hypoplasia, and growth retardation after weaning. Nat. Genet. 16:391-96
111. Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, et al. 2001. Extrarenal expression of 25-hydroxyvitamin D3-1α-hydroxylase. J. Clin. Endocr. Metab. 86:888-94
112. Zhu J, DeLuca HF. 2012. Vitamin D-25-hydroxylase: four decades of searching, are we there yet? Arch. Biochem. Biophys. 523:30-36
113. Zisman AL, Hristova M, Ho LT, Sprague SM. 2007. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am. J. Nephrol. 27:36-43